cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aeglea Biotherapeutics Inc
18 own
28 watching
Current Price
$0
$0
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
8.52M
52-Week High
52-Week High
1.56
52-Week Low
52-Week Low
0.1251
Average Volume
Average Volume
0.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization8.52M
icon52-Week High1.56
icon52-Week Low0.1251
iconAverage Volume0.14M
iconDividend Yield--
iconP/E Ratio--
What does the Aeglea Biotherapeutics Inc do?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
How much money does Aeglea Biotherapeutics Inc make?
News & Events about Aeglea Biotherapeutics Inc.
Ticker Report
1month ago
Investment analysts at StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research report issued on Wednesday. The firm set a hold rating on the biotechnology companys stock. AGLE has been the subject of a number of other ...
PR Newswire
1month ago
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of...
Zolmax
4 months ago
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research note released on Monday morning. The firm issued a hold rating on the biotechnology companys stock. AGLE has been the topic of several other research reports. Piper Sandler increased their target ...
PR Newswire
4 months ago
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables...
Zolmax
6 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...
Frequently Asked Questions
Frequently Asked Questions
What is Aeglea Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aeglea Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Aeglea Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aeglea Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aeglea Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aeglea Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aeglea Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aeglea Biotherapeutics Inc?
plus_minus_icon
What percentage is Aeglea Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aeglea Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00